We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+6.29%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$121B
AUM Growth
+$6.29B
Cap. Flow
+$257M
Cap. Flow %
0.21%
Top 10 Hldgs %
24.67%
Holding
4,045
New
183
Increased
1,650
Reduced
1,805
Closed
213

Top Buys

Rank Stock Value
1
AGG icon
iShares Core US Aggregate Bond ETF
AGG
+$753M
2
JCI icon
Johnson Controls International
JCI
+$159M
3
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$53.2M
4
IEF icon
iShares 7-10 Year Treasury Bond ETF
IEF
+$49.5M
5
VTEB icon
Vanguard Tax-Exempt Bond Index Fund
VTEB
+$47.2M

Top Sells

Rank Stock Value
1
USMV icon
iShares MSCI USA Min Vol Factor ETF
USMV
+$562M
2
AVGO icon
Broadcom
AVGO
+$124M
3
XLK icon
State Street Technology Select Sector SPDR ETF
XLK
+$102M
4
UNP icon
Union Pacific
UNP
+$89.7M
5
MSFT icon
Microsoft
MSFT
+$75.1M

Sector Composition

Rank Sector Weight
1 Technology 15.49%
2 Financials 8.61%
3 Healthcare 8.48%
4 Industrials 6.86%
5 Consumer Discretionary 5.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKBA icon
3776
Akebia Therapeutics
AKBA
$241M
$10.6K ﹤0.01%
+11,602
New +$11.2K
ACB
3777
Aurora Cannabis
ACB
$216M
$9.87K ﹤0.01%
1,847
-19
-1% -$112
ADAP
3778
DELISTED
Adaptimmune Therapeutics
ADAP
$9.66K ﹤0.01%
10,449
-849
-8% -$1.01K
JOB icon
3779
GEE Group
JOB
$21.7M
$9.22K ﹤0.01%
18,000
– –
KRRO icon
3780
Korro Bio
KRRO
$201M
$9K ﹤0.01%
520
+100
+24% +$1.94K
KGC icon
3781
CALL
Kinross Gold
KGC
$32.5B
$8.8K ﹤0.01%
2,200
– –
HYFM icon
3782
Hydrofarm Holdings
HYFM
$8.15M
$8.11K ﹤0.01%
1,038
-100
-9% -$1.2K
AMRS
3783
CALL
DELISTED
Amyris Inc.
AMRS
$8K ﹤0.01%
1,000
-16,600
-94% -$15.5K
BLPH
3784
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$7.66K ﹤0.01%
+11,097
New +$71.5K
ORIO
3785
Orion Digital Corp
ORIO
$16.6M
$7.37K ﹤0.01%
3,603
– –
POL
3786
DELISTED
Polished.com Inc.
POL
$7.27K ﹤0.01%
316
– –
FAZE
3787
DELISTED
FaZe Holdings Inc. Common Stock
FAZE
$7.05K ﹤0.01%
14,311
– –
INO icon
3788
Inovio Pharmaceuticals
INO
$80.8M
$6.82K ﹤0.01%
1,273
-66
-5% -$532
MDNA
3789
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$5.01K ﹤0.01%
10,400
– –
PVLA
3790
Palvella Therapeutics
PVLA
$2.23B
$4.96K ﹤0.01%
375
– –
NAK
3791
Northern Dynasty Minerals
NAK
$947M
$4.74K ﹤0.01%
19,734
-415
-2% -$94
GYRE icon
3792
Gyre Therapeutics
GYRE
$713M
$4.54K ﹤0.01%
860
-3,333
-79% -$11.9K
WE
3793
DELISTED
WeWork Inc.
WE
$2.6K ﹤0.01%
255
-125
-33% -$1.73K
HLGN
3794
DELISTED
Heliogen, Inc.
HLGN
$2.45K ﹤0.01%
286
– –
STEM icon
3795
CALL
Stem
STEM
$51.6M
$1.5K ﹤0.01%
10
– –
BODY.WS
3796
DELISTED
The Beachbody Company, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
BODY.WS
$516 ﹤0.01%
11,199
– –
NOGNW
3797
DELISTED
Nogin, Inc. Warrant
NOGNW
$181 ﹤0.01%
14,287
– –
ACMR icon
3798
ACM Research
ACMR
$5.55B
– –
-11,035
Closed -$129K
ACNB icon
3799
ACNB Corp
ACNB
$646M
– –
-7,432
Closed -$242K
AMAL icon
3800
Amalgamated Financial
AMAL
$1.49B
– –
-14,925
Closed -$264K
150 151
152
153 154

Similar funds

RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
PI
PEAK6 Investments Chicago, Illinois $44.8B AUM 19.99% 1-Year Est. Return
ECU
Eisler Capital (UK) London, United Kingdom $21.7B AUM 0.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
AA
Axiom Advisory San Diego, California $10.7B AUM 25.51% 1-Year Est. Return
SA
SpiderRock Advisors Wilimington, Delaware $6.29B AUM
WPL
Winder Pte Ltd Singapore $5.59B AUM 41.5% 1-Year Est. Return
ECU
Eisler Capital (US) New York $4.67B AUM 35.2% 1-Year Est. Return

Raymond James & Associates's Q2 2023 Portfolio in Review

As of Q2 2023, Raymond James & Associates held 4,045 positions worth $121B, up 5.5% from $115B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Raymond James & Associates's Q2 2023 filing shows 183 new, 1,650 increased, 1,805 reduced and 213 closed positions. Its largest new stake was Choice Hotels: 212,259 shares worth $24.9M. The largest sale was iShares MSCI USA Min Vol Factor ETF, an estimated $562M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q2 2023 buy was Choice Hotels: 212,259 shares worth $24.9M.
  • Raymond James & Associates added most to iShares Core US Aggregate Bond ETF in Q2 2023, an estimated $753M increase.
  • Raymond James & Associates's biggest Q2 2023 reduction was iShares MSCI USA Min Vol Factor ETF, cutting an estimated $562M.
  • Raymond James & Associates fully exited ABB Ltd in Q2 2023, selling an estimated $17.1M.
  • Raymond James & Associates's ten largest holdings make up 25% of its $121B portfolio in Q2 2023.
  • Raymond James & Associates opened 183 new positions and closed 213 in Q2 2023.
  • Raymond James & Associates's portfolio value rose 5.5% quarter-over-quarter to $121B.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.